vs
Midland States Bancorp, Inc.（MSBI）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
Midland States Bancorp, Inc.的季度营收约是RIGEL PHARMACEUTICALS INC的1.1倍（$79.5M vs $69.8M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs 23.2%，领先360.8%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs -6.4%）
雷德尼爾銀行公司是總部位於西雅圖的雷德尼爾國家銀行的母公司，該銀行是華盛頓州的本土銀行，在全州設有多家網點。其發展歷史可追溯至1889年理查德·霍利約克創辦的通商國家銀行，1974年正式更名為雷德尼爾國家銀行，此後陸續收購機構，將業務拓展至阿拉斯加與俄勒岡地區。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
MSBI vs RIGL — 直观对比
营收规模更大
MSBI
是对方的1.1倍
$69.8M
净利率更高
RIGL
高出360.8%
23.2%
两年增速更快
RIGL
近两年复合增速
-6.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $79.5M | $69.8M |
| 净利润 | $18.5M | $268.1M |
| 毛利率 | — | 91.5% |
| 营业利润率 | — | 33.2% |
| 净利率 | 23.2% | 384.0% |
| 营收同比 | — | 21.2% |
| 净利润同比 | 739.3% | 1769.2% |
| 每股收益（稀释后） | $0.74 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MSBIRIGL
| Q1 26 | $79.5M | — | ||
| Q4 25 | $85.6M | $69.8M | ||
| Q3 25 | $81.1M | $69.5M | ||
| Q2 25 | $82.2M | $101.7M | ||
| Q1 25 | $76.1M | $53.3M | ||
| Q4 24 | $93.9M | $57.6M | ||
| Q3 24 | $92.7M | $55.3M | ||
| Q2 24 | $90.9M | $36.8M |
净利润MSBIRIGL
| Q1 26 | $18.5M | — | ||
| Q4 25 | $-2.9M | $268.1M | ||
| Q3 25 | $7.6M | $27.9M | ||
| Q2 25 | $12.0M | $59.6M | ||
| Q1 25 | $-141.0M | $11.4M | ||
| Q4 24 | $-30.8M | $14.3M | ||
| Q3 24 | $20.4M | $12.4M | ||
| Q2 24 | $25.7M | $-1.0M |
毛利率MSBIRIGL
| Q1 26 | — | — | ||
| Q4 25 | — | 91.5% | ||
| Q3 25 | — | 93.2% | ||
| Q2 25 | — | 95.6% | ||
| Q1 25 | — | 91.7% | ||
| Q4 24 | — | 89.9% | ||
| Q3 24 | — | 85.5% | ||
| Q2 24 | — | 92.4% |
营业利润率MSBIRIGL
| Q1 26 | — | — | ||
| Q4 25 | -5.5% | 33.2% | ||
| Q3 25 | 13.9% | 40.9% | ||
| Q2 25 | 18.1% | 60.1% | ||
| Q1 25 | -181.2% | 23.9% | ||
| Q4 24 | -66.5% | 28.9% | ||
| Q3 24 | 26.9% | 25.4% | ||
| Q2 24 | 35.0% | 1.2% |
净利率MSBIRIGL
| Q1 26 | 23.2% | — | ||
| Q4 25 | -4.9% | 384.0% | ||
| Q3 25 | 9.3% | 40.2% | ||
| Q2 25 | 14.6% | 58.6% | ||
| Q1 25 | -185.4% | 21.5% | ||
| Q4 24 | -52.5% | 24.9% | ||
| Q3 24 | 22.1% | 22.5% | ||
| Q2 24 | 28.3% | -2.8% |
每股收益（稀释后）MSBIRIGL
| Q1 26 | $0.74 | — | ||
| Q4 25 | $-0.22 | $14.11 | ||
| Q3 25 | $0.24 | $1.46 | ||
| Q2 25 | $0.44 | $3.28 | ||
| Q1 25 | $-6.58 | $0.63 | ||
| Q4 24 | $-1.49 | $0.82 | ||
| Q3 24 | $0.83 | $0.70 | ||
| Q2 24 | $1.06 | $-0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $89.4M | $155.0M |
| 总债务越低越好 | $33.2M | $52.5M |
| 股东权益账面价值 | $569.5M | $391.5M |
| 总资产 | $6.5B | $513.6M |
| 负债/权益比越低杠杆越低 | 0.06× | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资MSBIRIGL
| Q1 26 | $89.4M | — | ||
| Q4 25 | $127.8M | $155.0M | ||
| Q3 25 | $166.1M | $137.1M | ||
| Q2 25 | $176.6M | $108.4M | ||
| Q1 25 | $102.0M | $77.1M | ||
| Q4 24 | $114.8M | $77.3M | ||
| Q3 24 | $121.9M | $61.1M | ||
| Q2 24 | $124.6M | $49.1M |
总债务MSBIRIGL
| Q1 26 | $33.2M | — | ||
| Q4 25 | — | $52.5M | ||
| Q3 25 | — | $60.0M | ||
| Q2 25 | — | $60.0M | ||
| Q1 25 | — | $60.0M | ||
| Q4 24 | — | $60.0M | ||
| Q3 24 | — | $60.0M | ||
| Q2 24 | — | $60.0M |
股东权益MSBIRIGL
| Q1 26 | $569.5M | — | ||
| Q4 25 | $565.5M | $391.5M | ||
| Q3 25 | $584.0M | $117.6M | ||
| Q2 25 | $573.7M | $81.9M | ||
| Q1 25 | $571.4M | $18.6M | ||
| Q4 24 | $710.8M | $3.3M | ||
| Q3 24 | $771.2M | $-14.6M | ||
| Q2 24 | $736.8M | $-29.9M |
总资产MSBIRIGL
| Q1 26 | $6.5B | — | ||
| Q4 25 | $6.5B | $513.6M | ||
| Q3 25 | $6.9B | $242.5M | ||
| Q2 25 | $7.1B | $206.7M | ||
| Q1 25 | $7.3B | $176.0M | ||
| Q4 24 | $7.5B | $164.0M | ||
| Q3 24 | $7.7B | $139.4M | ||
| Q2 24 | $7.7B | $128.4M |
负债/权益比MSBIRIGL
| Q1 26 | 0.06× | — | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 3.23× | ||
| Q4 24 | — | 18.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $22.0M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 0.08× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流MSBIRIGL
| Q1 26 | — | — | ||
| Q4 25 | $125.7M | $22.0M | ||
| Q3 25 | $80.0M | $24.0M | ||
| Q2 25 | $28.1M | $30.5M | ||
| Q1 25 | $24.7M | $-893.0K | ||
| Q4 24 | $176.5M | $14.5M | ||
| Q3 24 | $46.5M | $21.7M | ||
| Q2 24 | $31.4M | $302.0K |
自由现金流MSBIRIGL
| Q1 26 | — | — | ||
| Q4 25 | $120.3M | — | ||
| Q3 25 | $78.6M | — | ||
| Q2 25 | $26.7M | — | ||
| Q1 25 | $22.9M | — | ||
| Q4 24 | $169.6M | — | ||
| Q3 24 | $44.4M | — | ||
| Q2 24 | $29.9M | — |
自由现金流率MSBIRIGL
| Q1 26 | — | — | ||
| Q4 25 | 140.6% | — | ||
| Q3 25 | 96.9% | — | ||
| Q2 25 | 32.4% | — | ||
| Q1 25 | 30.1% | — | ||
| Q4 24 | 180.6% | — | ||
| Q3 24 | 47.9% | — | ||
| Q2 24 | 32.9% | — |
资本支出强度MSBIRIGL
| Q1 26 | — | — | ||
| Q4 25 | 6.2% | — | ||
| Q3 25 | 1.7% | — | ||
| Q2 25 | 1.7% | — | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 7.3% | — | ||
| Q3 24 | 2.3% | — | ||
| Q2 24 | 1.7% | — |
现金转化率MSBIRIGL
| Q1 26 | — | — | ||
| Q4 25 | — | 0.08× | ||
| Q3 25 | 10.58× | 0.86× | ||
| Q2 25 | 2.33× | 0.51× | ||
| Q1 25 | — | -0.08× | ||
| Q4 24 | — | 1.01× | ||
| Q3 24 | 2.28× | 1.75× | ||
| Q2 24 | 1.22× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MSBI
| Net Interest Income | $57.4M | 72% |
| Noninterest Income | $22.1M | 28% |
RIGL
暂无分部数据
